Critical Care Medicine
Gastrointestinal Emergencies: Necrotizing Enterocolitis (NEC)
Necrotizing Enterocolitis (NEC)
1. Description of the problem
NEC is characterized by ischemia and necrosis of the gastrointestinal tract and can lead to mortality and morbidity, including short bowel syndrome. It is most often found in premature infants and requires early recognition and treatment to prevent long segment bowel necrosis.
Clinical features
Most infants diagnosed with NEC are premature but are relatively healthy and feeding well prior to the development of NEC.
Feeding intolerance
Apnea/respiratory failure
Signs of sepsis
Abdominal distention
Hematochezia
Lack of bowel sounds
Key management points
Early Identification - pneumatosis intestinalis and ileus on AXR
Early Treatment - antibiotics, cessation of oral feeding, possible surgical exploration
Serial abdominal X-rays
3. Diagnosis
The mainstay of NEC diagnosis remains abdominal radiography, although abdominal ultrasound may have some utility, especially with ultrasound expertise.
AXR - dilated bowel loops, ileus, pneumatosis intestinalis, pneumoperitoneum, fixed loops
While the diagnosis of NEC relies on radiographic evidence, laboratory evaluation may further suggest NEC. These findings include:
Metabolic acidosis
Low platelets
Low neutrophil count
Prolonged PT/PTT
High glucose
4. Specific Treatment
Medical Management
Fluid resuscitation and replacement of insensible losses
Bowel rest with NG suction
Total parenteral nutrition
Antibiotic coverage (see below)
Radiographic monitoring
Surgical Management
Laparotomy with resection of necrotic bowel and peritoneal drain placement
Drugs and dosages
Vancomycin, gentamicin, and clindamycin or metronidazole or piperacillin-tazobactam.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |